| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Mersana Therapeutics, Inc.
13D/A
MRSN · 59045L205
|
0% |
1/8/2026
Event 1/6/2026
|
||||
| Bain Capital Life Sciences Fund II, L.P. | 0% | |||||
| BCIP Life Sciences Associates, LP | 0% | |||||
| BCLS II Investco, LP | 0% | |||||
|
Savara Inc.
13D/A
SVRA · 805111101
|
10.0% |
3/27/2025
Event 3/25/2025
|
||||
| Bain Capital Life Sciences Fund II, L.P. | 10.0% | |||||
| BCIP Life Sciences Associates, LP | 10.0% | |||||
| BCLS II Investco, LP | 10.0% | |||||
| Schedule 13G · 3 securities · passive | ||||||
|
Xilio Therapeutics, Inc.
13G/A
XLO · 98422T209
|
10.0% |
5/15/2026
Event 3/31/2026
|
||||
| BCLS II Equity Opportunities, LP | 10.0% | |||||
| Bain Capital Life Sciences Fund II, L.P. | 0% | |||||
| BCIP Life Sciences Associates, LP | 0% | |||||
|
Xilio Therapeutics, Inc.
13G/A
XLO · 98422T100
|
8.5% |
2/17/2026
Event 12/31/2025
|
||||
| Bain Capital Life Sciences Fund II, L.P. | 1.3% | |||||
| BCIP Life Sciences Associates, LP | 0.2% | |||||
| BCLS II Equity Opportunities, LP | 8.5% | |||||
| BCLS II Investco, LP | 0% | |||||
|
C4 Therapeutics, Inc.
13G
CCCC · 12529R107
|
6.3% |
10/24/2025
Event 10/17/2025
|
||||
| Bain Capital Life Sciences Fund II, L.P. | 1.1% | |||||
| BCIP Life Sciences Associates, LP | 0.1% | |||||
| BCLS II Equity Opportunities, LP | 6.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.